Articles from Scribe Therapeutics Inc.

Scribe Therapeutics Inc. (“Scribe”), a genetic medicines company pioneering next-generation in vivo CRISPR-based medicines designed to be safe, durable, and effective enough to become standard-of-care treatments for prevalent diseases, presented breakthrough preclinical data across its cardiometabolic pipeline (STX-1150 for LDL-C lowering, STX-1200 for Lp(a) lowering, and STX-1400 for triglyceride lowering) at the American Heart Association (AHA) Scientific Sessions 2025.

Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, recently presented new breakthrough data from two of its core platforms. At the European Society of Cardiology (ESC) Congress, Scribe presented results from STX-1200, its next-generation CasXE-based therapy, showing strong potency and precision in lowering lipoprotein(a) (Lp(a)), a major and under-addressed driver of cardiovascular disease. At the Cold Spring Harbor Laboratory (CSHL) Genome Engineering meeting, the company unveiled DeepXE, its proprietary AI-powered CRISPR design platform that accurately predicts gRNA editing efficiency, outperforming existing Cas9-based predictive models, thereby enabling the more rapid development and deployment of precise and effective genome-editing treatments.

Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, presented data on two therapeutic applications of its genome editing and epigenetic silencing technologies at recent medical and scientific conferences.

Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced its participation in the 28th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place May 13-17, 2025, at the Ernest N. Morial Convention Center in New Orleans, LA.

Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced a late-breaking oral presentation at the 93rd European Atherosclerosis Society (EAS) Congress taking place between May 4-7, 2025, at the Scottish Event Campus in Glasgow, United Kingdom.

Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, presented data on its Epigenetic Long-Term X-Repressor (ELXR) technology at the 2025 Keystone Symposia on “Precision Genome Engineering: Translating the Human Genome to the Clinic” conference. The Symposia Spotlight presentation showcases Scribe’s CRISPR by DesignTM approach to engineering potent ELXRs with newly uncovered repressor domains and their validation in animal models, including non-human primates. Notably, a single dose of ELXR using a newly identified repressor domain achieved ~90% repression of PCSK9—a key driver of dyslipidemia—lasting at least 150 days in non-human primates. The identification and use of a newly discovered repressor domain enables the creation of more effective epigenetic editors with a broader therapeutic window than current Cas9-based repressors.

Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced its participation in the following conferences:

Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced the achievement of a success milestone for one of the targets in its research collaboration with Sanofi to develop in vivo CRISPR-based therapeutics. Scribe is eligible to receive over $1.2 billion across all programs in milestone payments for the achievement of certain research, development, regulatory and commercial milestones, as well as high-single-digit to mid-teen royalties.

Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced that Benjamin Oakes, Ph.D., Chief Executive Officer of Scribe, will present at the 43rd Annual J.P. Morgan Healthcare Conference on Monday, January 13, 2025 at 4:30 p.m. PT in San Francisco, CA.

Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, presented preclinical data on its CRISPR X-Editor (XE) and Epigenetic Long-Term X-Repressor (ELXR) technologies at the American Heart Association’s Scientific Sessions 2024.

Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced its participation in the American Heart Association’s Scientific Sessions taking place in Chicago, IL, from November 15-18, 2024.

Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced that the Company will participate in the following conferences in September and October:

Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, presented data on its X-Editor (XE) and Epigenetic Long-Term X-Repressor (ELXR) technologies at the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting taking place in Baltimore, MD, and virtually.

Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced its participation in the 27th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place at the Baltimore Convention Center in Baltimore, MD, and virtually from May 7-11, 2024.

Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced that co-founder and CEO Benjamin Oakes, Ph.D., and CFO David Parrot will participate in the upcoming Leerink Partners Global Biopharma Conference on Tuesday, March 12, 2024 and Wednesday, March 13, 2024 in Miami Beach, FL.

Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced that Sanofi (NASDAQ: SNY) has exercised its option for a second target as part of the companies' research collaboration to develop in vivo CRISPR-based therapeutics.

Scribe Therapeutics Inc. (Scribe), a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced that Benjamin Oakes, Ph.D., Chief Executive Officer of Scribe, will present at the 42nd Annual J.P. Morgan Healthcare Conference on Monday, January 8, 2024 at 4:30 p.m. PT in San Francisco, CA.

Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced the appointments of Aarif Khakoo, M.D., M.B.A., as Chief Scientific Officer and Head of Research and Development (R&D), and Maria Mirotsou, M.Sc., Ph.D., as Vice President of Discovery Biology.

Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced an expanded collaboration with Sanofi (NASDAQ: SNY). Under the agreement, Sanofi receives an exclusive license to use Scribe’s CRISPR X-Editing (XE) genome editing technologies for the development of in vivo therapies, including sickle cell disease. The agreement follows the launch of the companies’ existing collaboration focused on ex vivo editing of natural killer (NK) cell therapies for the treatment of cancer.

Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, will present data on its X-Editing (XE) technologies today at the 26th American Society of Gene and Cell Therapy (ASGCT) Annual Meeting being held in Los Angeles, Calif. and virtually. The data validate the company’s CRISPR by Design™ approach as well as its XE technology as a potent and flexible platform for gene editing.

Scribe Therapeutics Inc., a genetic medicines company unlocking the potential of CRISPR to transform human health, today announced a strategic collaboration with Prevail Therapeutics, a wholly owned subsidiary of Eli Lilly and Company, granting Prevail exclusive rights to Scribe’s CRISPR X-Editing (XE) technologies for the development of in vivo therapies directed to specified targets known to cause serious neurological and neuromuscular diseases.

Scribe Therapeutics Inc., a molecular engineering company creating genetic medicines through its CRISPR by Design™ approach to genetic modification, today announced a presentation on its X-Editor (XE) technology at the 26th American Society of Gene & Cell Therapy (ASGCT) Annual Meeting, taking place in Los Angeles, Calif. and virtually from May 16-20, 2023.

Scribe Therapeutics Inc., a molecular engineering company enabling the creation of genetic medicines through its CRISPR by Design™ approach to genetic modification, today announced it will participate in the upcoming Guggenheim Healthcare Talks: Genomic Medicines and Rare Disease Days, taking place from Monday, April 3 to Tuesday, April 4, 2023 in New York, NY.

Scribe Therapeutics Inc., a molecular engineering company pioneering a CRISPR by Design™ platform for genetic medicine, today announced it will participate in four upcoming conferences.

Scribe Therapeutics Inc., a molecular engineering company pioneering a CRISPR by Design™ platform for genetic medicine, today announced it will participate in two upcoming investor conferences:

Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced the expansion of its headquarters and addition of three vice presidents to its growing management team.

Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced its participation in the virtual Biopharma Private Company Connect event hosted by SVB Securities on July 20-21, 2022. Company executives, including CEO and co-founder Benjamin Oakes, PhD, and Chief Financial Officer David Parrot, will hold virtual one-on-one meetings with investors during the event. Meetings with the management team may be requested through SVB Securities.

Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, announced Biogen Inc. (Nasdaq:BIIB) has exercised an option for an additional disease target in gene therapy as part of the companies’ ongoing research collaboration to develop and commercialize CRISPR-based medicines. The expanded collaboration further validates Scribe’s position as a leading organization driving the development of novel CRISPR-based therapeutics that treat the underlying cause of disease.

Scribe Therapeutics Inc., a molecular engineering company creating the most advanced technologies for CRISPR-based genetic medicine, today announced its participation in the Goldman Sachs The New Guard: Privates Leading The Disruption In Healthcare conference.